Anand Sivaraman

Remidio has pioneered innovations that deliver specialist care to primary care and to patient homes. We're not just creating medical devices; we're crafting a revolution in risk triaging that hinges on advanced, on the edge Artificial Intelligence algorithms and user-friendly point-of-care devices. Our focus is on bridging healthcare gaps, enabling effective risk triaging, diagnosis and management of ocular and systemic diseases, using the Eye as a Scalable Sensor. This is the science of Oculomics. This is made possible by a strong commitment to investments in both Clinical Research and Product Development - every product goes through prospective, on-field, real world validation by specialist doctors, that are published in open access scientific publications. Our focus on hardware and AI technology and product Research and Development has led to 35 filed and 13 granted patents in US, China JP, EU and India, and 85+ peer-reviewed publications. More than 1500+ devices are brought to market each year at Remidio, through a robust, integrated Quality Management System. Our commitment has led to the deployment of nearly 5,000 product solutions, touching the lives of 15 million patients, in nearly 5 countries, but with a strong focus on India and the US. Nearly 800 are detected with Glaucoma and 4000 with Diabetic Retinopathy every month, thanks to the use of our Medios AI algorithms in Primary care, Ophthalmology Clinics, Vision Centers. We are now looking to extend this model to Diabetes management, CVD, CKD and Liver Disease and Maternal Health. With a focus on product, delivery and business model innovation, Remidio has forged a path that brings regulatory-approved, best-in-class solutions to both developing and developed nations.It's about challenging healthcare norms and proving that innovation can be universally relevant and impactful, if done with simplicity and purpose.